{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T16:03:11Z","timestamp":1700582591158},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s10147-009-0904-5","type":"journal-article","created":{"date-parts":[[2009,7,10]],"date-time":"2009-07-10T13:21:21Z","timestamp":1247232081000},"page":"191-196","source":"Crossref","is-referenced-by-count":1,"title":["Recent advances in the treatment of follicular lymphoma"],"prefix":"10.1007","volume":"14","author":[{"given":"Yukio","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,7,11]]},"reference":[{"issue":"suppl4","key":"904_CR1","first-page":"129","volume":"19","author":"R. Levy","year":"2008","unstructured":"Levy R, Houot R, Brody J, Czerwinski D (2008) New immunologic treatment for lymphoma. Ann Oncol 19:suppl 4, 129 (Abstract)","journal-title":"Ann Oncol"},{"key":"904_CR2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.blre.2008.09.001","volume":"23","author":"R. Houot","year":"2008","unstructured":"Houot R, Levy R (2008) Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev 23:137\u2013142","journal-title":"Blood Rev"},{"key":"904_CR3","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","volume":"111","author":"A. Hagenbeek","year":"2008","unstructured":"Hagenbeek A, Gadeberg O, Johnson P, et al. (2008) First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial. Blood 111:5486\u20135495","journal-title":"Blood"},{"key":"904_CR4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.cji.0000155050.03916.04","volume":"28","author":"Y. Vugmeyster","year":"2005","unstructured":"Vugmeyster Y, Beyer J, Howell K, et al. (2005) Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother 28:212\u2013219","journal-title":"J Immunother"},{"key":"904_CR5","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/1078-0432.CCR-03-0493","volume":"10","author":"R. Stein","year":"2004","unstructured":"Stein R, Qu Z, Chen S, et al. (2004) Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin\u2019s lymphoma. Clin Cancer Res 10:2868\u20132878","journal-title":"Clin Cancer Res"},{"issue":"Suppl4","key":"904_CR6","doi-asserted-by":"crossref","first-page":"iv 60","DOI":"10.1093\/annonc\/mdn199","volume":"19","author":"J.P. Leonard","year":"2008","unstructured":"Leonard JP, Martin P, Ruan J, et al. (2008) New monoclonal antibodies for non-Hodgkin\u2019s lymphoma. Ann Oncol 19(Suppl 4):iv 60\u201362","journal-title":"Ann Oncol"},{"key":"904_CR7","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1182\/blood-2006-04-020057","volume":"108","author":"J.A. Bowles","year":"2006","unstructured":"Bowles JA, Wang SY, Link BK, et al. (2006) Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108:2648\u20132654","journal-title":"Blood"},{"key":"904_CR8","doi-asserted-by":"crossref","first-page":"229a","DOI":"10.1182\/blood.V108.11.229.229","volume":"108","author":"P. Umena","year":"2006","unstructured":"Umena P, Moessner EPB (2006) Novel third generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. Blood 108:229a (Abstract)","journal-title":"Blood"},{"key":"904_CR9","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","volume":"25","author":"P. Hillmen","year":"2007","unstructured":"Hillmen P, Skotnicki AB, Robak T, et al. (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616\u20135623","journal-title":"J Clin Oncol"},{"key":"904_CR10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/annonc\/mdn666","volume":"20","author":"J. Ruan","year":"2009","unstructured":"Ruan J, Hajjar K, Rafii S, Leonard JP (2009) Angiogenesis and antiangiogenic therapy in non-Hodgkin\u2019s lymphoma. Ann Oncol 20:413\u2013424","journal-title":"Ann Oncol"},{"key":"904_CR11","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/annonc\/mdm114","volume":"18","author":"J.P. Leonard","year":"2007","unstructured":"Leonard JP, Friedberg JW, Younes A, et al. (2007) A phase I\/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 18:1216\u20131223","journal-title":"Ann Oncol"},{"key":"904_CR12","doi-asserted-by":"crossref","first-page":"209a","DOI":"10.1182\/blood-2005-12-4897","volume":"108","author":"R. Advani","year":"2006","unstructured":"Advani R, ForeroTorres A, Furman R (2006) SGN-40 (antihiCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin\u2019s lymphoma: evidence of anti-tumor activity from a phase I study. Blood 108:209a (Abstract)","journal-title":"Blood"},{"key":"904_CR13","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1038\/sj.onc.1210370","volume":"26","author":"J.P. Leonard","year":"2007","unstructured":"Leonard JP, Goldenberg DM (2007) Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 26:3704\u20133713","journal-title":"Oncogene"},{"key":"904_CR14","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1200\/JCO.2005.13.821","volume":"23","author":"J.P. Leonard","year":"2005","unstructured":"Leonard JP, Coleman M, Ketas J, et al. (2005) Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin\u2019s lymphoma. J Clin Oncol 23:5044\u20135051","journal-title":"J Clin Oncol"},{"key":"904_CR15","doi-asserted-by":"crossref","first-page":"2837a","DOI":"10.1182\/blood.V108.11.2837.2837","volume":"108","author":"J. Byrd","year":"2006","unstructured":"Byrd J, Flinn I, Khan K. (2006) Pharmacokinetics and pharmacodynamics from a first-in-human phase I dose escalation study with antagonist anti-CD40 antibody, HCD 122 (formerly CHIR-12.12), in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 108:2837a (Abstract)","journal-title":"Blood"},{"key":"904_CR16","doi-asserted-by":"crossref","first-page":"14a","DOI":"10.1182\/blood.V108.11.14.14","volume":"108","author":"J. Byrd","year":"2006","unstructured":"Byrd J, Castro J, O\u2019Brien S (2006) Comparison of results from a phase I\/II study of lumiliximab (anti-CD23) in combination with FCR for patients with relapsed CLL with published PCR results. Blood 108:14a (Abstract)","journal-title":"Blood"},{"key":"904_CR17","first-page":"606a","volume":"98","author":"B.K. Link","year":"2001","unstructured":"Link BK, Kahl B, Czuczman M, et al. (2001) A phase II study of remitogen (Hu1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone\/MALT B-cell lymphoma. Blood 98:606a (Abstract)","journal-title":"Blood"},{"key":"904_CR18","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-04-017921","volume":"108","author":"R. Stein","year":"2006","unstructured":"Stein R, Qu Z, Chen S, et al. (2006) Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood 108:2736\u20132744","journal-title":"Blood"},{"key":"904_CR19","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"T.E. Witzig","year":"2002","unstructured":"Witzig TE, Flinn IW, Gordon LI, et al. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma. J Clin Oncol 20:3262\u20133269","journal-title":"J Clin Oncol"},{"key":"904_CR20","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"T.E. Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, et al. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radio-immunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 20:2453\u20132463","journal-title":"J Clin Oncol"},{"key":"904_CR21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0093-7754(03)00237-9","volume":"30","author":"C. Emmanouilides","year":"2003","unstructured":"Emmanouilides C (2003) Radioimmunotherapy for non-Hodgkin\u2019s lymphoma. Semin Oncol 30:531\u2013544","journal-title":"Semin Oncol"},{"key":"904_CR22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"M.S. Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J, et al. (2005) 131I-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441\u2013449","journal-title":"N Engl J Med"},{"key":"904_CR23","doi-asserted-by":"crossref","first-page":"555a","DOI":"10.1182\/blood.V112.11.1565.1565","volume":"112","author":"K. Tobinai","year":"2008","unstructured":"Tobinai K, Ogura M, Hatake K, et al. (2008) Phase 1 and pharmacokinetic study of inotuzumab ozogamicin (CMC-544) as a single agent in Japanese patients with follicular lymphoma pretreated with rituximab. Blood 112:555a (Abstract)","journal-title":"Blood"},{"key":"904_CR24","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/ijc.23626","volume":"123","author":"M. Stanglmaier","year":"2008","unstructured":"Stanglmaier M, Faltin M, Ruf P, et al. (2008) Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 \u00d7 anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer 123:1181\u20131189","journal-title":"Int J Cancer"},{"key":"904_CR25","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","volume":"110","author":"X. Zhao","year":"2007","unstructured":"Zhao X, Lapalombella R, Joshi T, et al. (2007) Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110:2569\u20132577","journal-title":"Blood"},{"key":"904_CR26","doi-asserted-by":"crossref","first-page":"703a","DOI":"10.1200\/jco.2007.25.18_suppl.18521","volume":"25","author":"K. Tobinai","year":"2007","unstructured":"Tobinai K, Watanabe T, Kobayashia Y, et al. (2007) Phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients (pts) with non-Hodgkin lymphoma (NHL) in Japan. J Clin Oncol 25:703a","journal-title":"J Clin Oncol"},{"key":"904_CR27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A. Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P, et al. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 23:667\u2013675","journal-title":"J Clin Oncol"},{"key":"904_CR28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3816\/CLM.2005.n.046","volume":"6","author":"O.A. O\u2019Connor","year":"2005","unstructured":"O\u2019Connor OA (2005) Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clin Lymphoma Myeloma 6:191\u2013199","journal-title":"Clin Lymphoma Myeloma"},{"key":"904_CR29","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","volume":"27","author":"B.D. Cheson","year":"2009","unstructured":"Cheson BD, Rummel MJ (2009) Bendamustine: rebirth of an old drug. J Clin Oncol 27:1492\u20131501","journal-title":"J Clin Oncol"},{"key":"904_CR30","doi-asserted-by":"crossref","unstructured":"Kato M, Sanada M, Kato I, et al. (2009) Frequent inactivation of A20 in B-cell lymphomas. Nature May 3. [Epub ahead of print]","DOI":"10.1038\/nature07969"},{"key":"904_CR31","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1182\/blood.V84.4.1043.1043","volume":"84","author":"H. Tilly","year":"1994","unstructured":"Tilly H, Rossi A, Stamatoullas A, et al. (1994) Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84:1043\u20131049","journal-title":"Blood"},{"key":"904_CR32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2008-02-140616","volume":"113","author":"K.J. Cheung","year":"2009","unstructured":"Cheung KJ, Shah SP, Steidl C, et al. (2009) Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood 113:137\u2013148","journal-title":"Blood"},{"key":"904_CR33","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1182\/blood-2008-08-174953","volume":"113","author":"D. O\u2019shea","year":"2009","unstructured":"O\u2019shea D, O\u2019Riain C, Gupta M, et al. (2009) Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood 113:2298\u20132301","journal-title":"Blood"},{"key":"904_CR34","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1172\/JCI26322","volume":"115","author":"J.L. Luo","year":"2005","unstructured":"Luo JL, Kamata H, Karin M (2005) IKK\/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 115:2625\u20132632","journal-title":"J Clin Invest"},{"key":"904_CR35","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","volume":"359","author":"B.D. Cheson","year":"2008","unstructured":"Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin\u2019s lymphoma. N Engl J Med 359:613\u2013626","journal-title":"N Engl J Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-009-0904-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-009-0904-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-009-0904-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T12:47:25Z","timestamp":1589978845000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-009-0904-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["904"],"URL":"https:\/\/doi.org\/10.1007\/s10147-009-0904-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}